Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
Status:
Active, not recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe
means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical
resection.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Providence Health & Services
Collaborator:
Providence Cancer Center, Earle A. Chiles Research Institute